Tecarfarin Anti-Coagulation Trial (TACT)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.
Also called NCT02522221
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,000 participants
- Sponsor
- Espero Biopharma
- Registry
-
NCT02522221
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT02522221. Randomized; no masking; primary purpose treatment. Start 2018-06-01 (anticipated); primary completion 2019-03-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Tecarfarin Anti-Coagulation Trial (TACT)
- Acronym
- TACT
- Condition
- Thromboembolism
- Condition
- Thrombosis
- Intervention (Drug)
- Warfarin
- Intervention (Drug)
- tecarfarin
- Lead sponsor
- Espero Biopharma
Record details
- Record id
cardio:ct-nct02522221- Content hash
1d19308fee89ea592d39bca014b518787897b52711dee05bb759580a6f181757